The phaseI,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer

The phaseI,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer - GAS Study I/II

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016630

Enrollment

Registered

2015-02-25

Start date

2015-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally-advanced pancreatic cancer

Interventions

gemcitabine+nab-paclitaxel+S-1 gemcitabine (Level I:800mg/m2) (Level II:1000mg/m2) nab-paclitaxel (Level I:100mg/m2) (Level II:125mg/m2) S-1 (65mg/m2)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Histologically confirmed pancreatic cancer (2)Locally advanced pancteatic cancer on imaging examinations (3)Performance status(ECOG):0-1 (4)Initial therapy (5)Agreement with signiture of aplicant has obtained before initiation of therapy

Exclusion criteria

Exclusion criteria: (1)severe allegy for medicine (2)Patients with other malignant disease within 5 years (3)Patients with active infection (4)Patients with severe neuropathy(>Grade2) (5)Patients with ileus (6)Patients with interstitial pneumonia (7)Patients with uncontrallable ascites or pleural fluid (8)Patients with uncontrallable diabetes (9)Patients with uncontrallable heart disease (10)Patients with pregnant or possibly pregnant (14)Patients who have judged not suitable for this study by doctor.

Design outcomes

Primary

Measure	Time frame
Phase I: incidence of adverse enent which apply for discontinuance criteria Phase II: 2 year survival rate, median survival time	—

Countries

Japan

Contacts

Public ContactNaru Kondo

Hiroshima University Institute of Biomedical and Health Sciences Applied Life Sciences Surgery

k-naru-surg@hiroshima-u.ac.jp082-257-5215

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026